Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Francine01on Dec 11, 2019 12:32pm
191 Views
Post# 30444239

RE:RE:RE:RE:RE:RE:RE:RE:RE:Feeling positive

RE:RE:RE:RE:RE:RE:RE:RE:RE:Feeling positive"Patatoes are cooked" my friends. In less than 10 days, we will know if it will be a billion dollars market cap company. 

My guess is that they will hit the 27%-28% TG reduction which will confirm that Acasti have a superior TG reduction profile than Amarin. 

In March, one or more secondary end points will be reached. 

In the meantime, financial markets are allergic to uncertainty and Acasti is an easy target for shorts and hedge funds. 

I think they are setting themself up for major short squeeze, they are waiting for the Amarin FDA approuval/expended label, they will announce the database lock up and shorty Ph3 positive results, this combined with the Amarin expended label will trigger an SP vertical lift. 

Don't be fooled by haters, shorts and Amarin frantic crowd.

GLTA
Bullboard Posts